COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

NCL News Archive

Tuesday, February 25, 2020

New Funding Opportunity

Toward Translation of Nanotechnology Cancer Interventions (TTNCI), PAR-20-116

The National Cancer Institute has just posted a new funding opportunity entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)". TTNCI is meant to enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/... View Post

Wednesday, February 5, 2020

Upcoming Application Deadline - March 2, 2020

The next deadline for application to NCL’s Assay Cascade characterization program is March 2, 2020. Visit our application and instructions page to download the template and review the evaluation criteria:

Have questions about the application, evaluation criteria, or the overall process? Please... View Post

Wednesday, October 16, 2019

NCL Leadership Changes

The NCL is proud to announce the appointment of Drs. Marina Dobrovolskaia and Stephan Stern as Laboratory Co-Directors. Dr. Dobrovolskaia will serve as Director of Operations for the lab, and Dr. Stern will serve as Director of Research & Development for the lab.

NCL will continue to support nanotech developers in their translational efforts by offering characterization and... View Post

Wednesday, October 16, 2019

NCL Assay Cascade—Back to Quarterly Application Deadlines

By popular request, the NCL will revert back to quarterly deadlines for the NCL’s Assay Cascade characterization service. The quarterly deadlines will be the first business days of March, June, September and December. The next application deadline will be December 2, 2019. For questions on the application process, email us at

Wednesday, October 16, 2019

Funding Opportunities & Translational Resources

The National Cancer Institute’s Nanodelivery Systems and Devices Branch has compiled the following list of funding opportunities and translational resources that may be of interest to nanotech developers. Click the link for each announcement to learn more.


PAR 20-284 – Innovative Research in Cancer Nanotechnology (R01... View Post

Friday, September 27, 2019

Online Workshop - Molecular & Cellular Immunology

FREE Online Workshop


December 2-6 and 9-12, 2019—11am-1pm EST


This two-part on-line workshop includes lectures covering fundamental... View Post

Friday, August 16, 2019

August 2019 Awardees Announced

The NCL solicits applications for the most promising cancer nanomedicine candidates for acceptance into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety,... View Post

Tuesday, July 23, 2019

Facilitating API Delivery with Nanoscale Solutions

The July issue of Pharmaceutical Technology highlights nanotechnology with interviews from Young-Ho Song, a research fellow at Pfizer Oncology, and NCL’s Stephan Stern. The article, written by Cynthia Challener, touches on some of the most promising avenues for nanotech—improving the therapeutic potential of existing drugs, resurrecting previously failed drugs, developing generics of current... View Post

Tuesday, July 23, 2019

Bioequivalence Studies: Doxil vs. Sun Pharma and Abraxane vs. Genexol-PM

The NCL recently completed a 2.5 year interagency collaboration with the US Food and Drug Administration (FDA) to evaluate the bioequivalence of marketed nanomedicines. The complexity of nanomedicine drug formulations poses unique scientific challenges. And, with the influx of generic versions of several nanomedicines now nearing clinical evaluation, these formulations pose unique regulatory... View Post

Wednesday, May 15, 2019

Identifying the Risk of Infusion Reactions

The NCL has just launched a new Technical Service to assess the potential for infusion reactions. Systemic administration of nanomedicines (and other therapies) have the potential to cause infusion reactions in patients, which often delays or halts their clinical translation. These reactions can manifest as fevers, chills, rigors, rashes, chest or back pain, or difficulty breathing, and, in... View Post